Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects (Q41122192)

From Wikidata

Jump to navigation Jump to search

scientific article published on July 2015

Language	Label	Description	Also known as
English	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects	scientific article published on July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Nadine Rouphael

18

object named as

Nadine Rouphael

0 references

2

object named as

Anna Wald

0 references

Christine Johnston

object named as

Christine Johnston

16

0 references

Patricia L Winokur

object named as

Patricia Winokur

10

0 references

Jack T Stapleton

object named as

Jack T Stapleton

5

0 references

19

object named as

Robert Atmar

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

11

object named as

Wendy Keitel

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Karen L Kotloff

22

object named as

Karen Kotloff

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Kathryn M. Edwards

8

object named as

Kathryn Edwards

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Srilatha Edupuganti

3

object named as

Srilatha Edupuganti

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Harry L Keyserling

9

object named as

Harry Keyserling

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Robert B Belshe

25

object named as

Robert B Belshe

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Mark J Mulligan

17

object named as

Mark Mulligan

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

4

object named as

Lisa A Jackson

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

1

object named as

Sharon E Frey

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Clarence Buddy Creech

23

object named as

C Buddy Creech

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

12

object named as

Heather Hill

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

author name string

Hana El Sahly

6

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Samer S El-Kamary

7

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Johannes B Goll

13

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Edwin L Anderson

14

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Irene L Graham

15

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Shital Patel

20

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Wilbur Chen

21

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Paul Chaplin

24

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

language of work or name

0 references

publication date

1 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

5225-5234

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Emergence and reemergence of smallpox: the need for development of a new generation smallpox vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Serum antibody responses after intradermal vaccination against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Intradermal hepatitis B vaccination in a large hospital employee population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Dose sparing with intradermal injection of influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Statistical considerations for noninferiority/equivalence trials in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

A prospective study of serum antibody and protection against smallpox

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Evaluation of smallpox vaccines using variola neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.075

7 January 2021

Identifiers

10.1016/J.VACCINE.2015.06.075

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41122192&oldid=2094089832"